CAPROCK Group Inc. purchased a new stake in GlaxoSmithKline plc (NYSE:GSK) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 5,686 shares of the pharmaceutical company’s stock, valued at approximately $229,000.
A number of other large investors have also modified their holdings of GSK. Clearstead Advisors LLC boosted its holdings in GlaxoSmithKline by 11.4% in the first quarter. Clearstead Advisors LLC now owns 2,682 shares of the pharmaceutical company’s stock valued at $96,000 after purchasing an additional 275 shares during the last quarter. Cutler Capital Management LLC boosted its position in shares of GlaxoSmithKline by 9.9% during the 2nd quarter. Cutler Capital Management LLC now owns 3,111 shares of the pharmaceutical company’s stock worth $124,000 after purchasing an additional 279 shares during the period. Kavar Capital Partners Group LLC boosted its position in shares of GlaxoSmithKline by 0.5% during the 1st quarter. Kavar Capital Partners Group LLC now owns 60,988 shares of the pharmaceutical company’s stock worth $2,177,000 after purchasing an additional 295 shares during the period. RMR Wealth Builders boosted its position in shares of GlaxoSmithKline by 67.1% during the 1st quarter. RMR Wealth Builders now owns 752 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 302 shares during the period. Finally, Founders Financial Alliance LLC boosted its position in GlaxoSmithKline by 4.5% in the 1st quarter. Founders Financial Alliance LLC now owns 7,039 shares of the pharmaceutical company’s stock valued at $266,000 after buying an additional 306 shares during the period. 12.25% of the stock is owned by institutional investors.
Several equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Friday, August 20th. Berenberg Bank reaffirmed a “buy” rating on shares of GlaxoSmithKline in a report on Thursday, August 19th. Deutsche Bank Aktiengesellschaft raised shares of GlaxoSmithKline from a “sell” rating to a “hold” rating in a research note on Wednesday, June 23rd. UBS Group reissued a “neutral” rating on shares of GlaxoSmithKline in a research note on Monday, September 20th. Finally, Zacks Investment Research cut shares of GlaxoSmithKline from a “hold” rating to a “sell” rating and set a $41.00 target price on the stock. in a research note on Tuesday, July 20th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, GlaxoSmithKline presently has an average rating of “Hold” and a consensus price target of $41.00.
GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 28th. The pharmaceutical company reported $0.79 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.54 by $0.25. GlaxoSmithKline had a net margin of 13.40% and a return on equity of 26.21%. The company had revenue of $11.31 billion during the quarter, compared to analyst estimates of $10.55 billion. On average, research analysts forecast that GlaxoSmithKline plc will post 2.77 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, October 7th. Shareholders of record on Friday, August 20th were issued a $0.523 dividend. This represents a $2.09 annualized dividend and a dividend yield of 5.39%. The ex-dividend date was Thursday, August 19th. GlaxoSmithKline’s payout ratio is 68.46%.
GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation.
Featured Article: Why is cost of goods sold important?
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.